(Esflurbiprofen + menthol) is a Small Molecule owned by Taisho Pharmaceutical Holdings, and is involved in 4 clinical trials, of which 3 were completed, and 1 is ongoing.

Esflurbiprofen is an anti-inflammatoryagent. It may result from the reversible inhibition of cyclooxygenase (COX-1 and COX-2), causing the peripheral inhibition of prostaglandin synthesis. Menthol has local anesthetic and counterirritant qualities.

The revenue for (Esflurbiprofen + menthol) is expected to reach a total of $718m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Esflurbiprofen + menthol) NPV Report.

(Esflurbiprofen + menthol) is currently owned by Taisho Pharmaceutical Holdings.

(Esflurbiprofen + menthol) Overview

Esflurbiprofen and Mentha oil/Menthol (Loqoa) is a fixed dose combination drug of which Esflurbiprofen is a propionic acid derivative is a non steriodal anti inflammatory drug acts as an analgesic agent and menthol acts as a counter-Irritant. It is formulated as patch for transdermal route of administration. Loqoa is indicated for treatment of osteoarthritis pain and inflammation. The drug candidate is under development for the treatment of scapulohumeral periarthritis and myalgia.

Taisho Pharmaceutical Holdings Overview

Taisho Pharmaceutical Holdings (Taisho Pharmaceutical) develops, manufactures and markets self-medication drugs and prescription pharmaceuticals. The company’s self-medication products comprise over the counter (OTC) products, quasi-drugs and health food products. Its prescription pharmaceuticals portfolio includes ethical drugs in the fields of infectious diseases, orthopedic disorders, central nervous system (CNS) diseases and metabolic diseases. Taisho Pharmaceutical provide its products under Pabron, Lipovitan D, Riup, Livita, Colac, Zosyn, Clarith, Edirol, Palux, Geninax, and Lorcam brand names. The company operates through its subsidiaries located in the Philippines, Indonesia, Malaysia, Thailand, Vietnam, China, Singapore, Taiwan and the US. Taisho Pharmaceutical is headquartered in Toshima-ku, Tokyo, Japan.

The company reported revenues of (Yen) JPY268,203 million for the fiscal year ended March 2022 (FY2022), a decrease of 4.9% over FY2021. In FY2022, the company’s operating margin was 3.7%, compared to an operating margin of 6.2% in FY2021. In FY2022, the company recorded a net margin of 4.9%, compared to a net margin of 4.7% in FY2021. The company reported revenues of JPY75,449 million for the second quarter ended September 2022, an increase of 9.2% over the previous quarter.

Quick View – (Esflurbiprofen + menthol)

Report Segments
  • Innovator (NME)
Drug Name
  • (Esflurbiprofen + menthol)
Administration Pathway
  • Topical
  • Transdermal
Therapeutic Areas
  • Central Nervous System
  • Musculoskeletal Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.